Search for: "MAJOR PHARMACEUTICALS" Results 201 - 220 of 4,367
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Jun 2023, 1:37 pm by Francis Pileggi
  The vice chancellor’s April 14 ruling was similar to his recent decision in a related shareholder suit over the opioid liability of pharmaceutical giant AmerisourceBergen. [read post]
12 Jun 2023, 1:09 pm by admin
Grant Steen, and Arturo Casadevall, “Misconduct accounts for the majority of retracted scientific publications,” 109 Proc. [read post]
12 Jun 2023, 5:00 am by Matthew Chun
Finally, at the advanced pharmaceutical manufacturing stage, AI/ML is being used to optimize process design (e.g., manufacturing process design), implement advanced process controls (e.g., dynamically adjusting multiple input parameters to maintain output parameters at desired levels), monitor equipment and products, and identify problem areas for continual improvement. [read post]
As a founding member of ICH, FDA plays a major role in the development of each of the ICH guidelines, which FDA and other regulatory authorities in ICH member countries through the globe commit to adopt and issue as guidance to industry. [read post]
1 Jun 2023, 2:23 pm by Geoff Schweller
The Court revived qui tam whistleblower lawsuits against pharmaceutical companies who allegedly overbilled Medicare and Medicaid. [read post]
29 May 2023, 5:04 am by Kluwer Patent blogger
Augenstein argued: ‘As there are only very few countries with technically qualified judges, it was absolutely clear that the vast majority of technically qualified judges – who are appointed part time and will only be renumerated on an hourly basis  – would work in parallel in private practice or in the industry. [read post]
25 May 2023, 4:15 am by Eli Mazour
After over 47 years of focusing on pharmaceutical patents, Tom has the unique vantage point of someone who saw the field explode after the passage of the Hatch-Waxman Act and the creation of the Federal Circuit. [read post]
25 May 2023, 4:15 am by Eli Mazour
After over 47 years of focusing on pharmaceutical patents, Tom has the unique vantage point of someone who saw the field explode after the passage of the Hatch-Waxman Act and the creation of the Federal Circuit. [read post]
21 May 2023, 1:37 pm by Francis Pileggi
  The vice chancellor’s April 14 ruling was similar to his recent decision in a related shareholder suit over the opioid liability of pharmaceutical giant AmerisourceBergen. [read post]
18 May 2023, 8:01 am by John Elwood
Most surprisingly to me, the court denied review in Teva Pharmaceuticals USA, Inc. v. [read post]
16 May 2023, 9:01 pm by Neil H. Buchanan and Michael C. Dorf
”How about agribusiness subsidies, corporate welfare, public spending on overpriced pharmaceuticals—or congressional salaries? [read post]
11 May 2023, 2:21 am by Aida Tohala (Bristows)
Erred in law because he applied the standard of plausibility laid down by the majority in Warner-Lambert when he should have applied the minority’s standard, or the standard of the majority but less strictly. [read post]
10 May 2023, 3:43 pm by Howard Knopf
Indeed, certain major media companies are now simultaneously major players as ISPs, copyright owners, and copyright users in various proceedings in various fora. [read post]
9 May 2023, 11:55 am by Zamansky LLC
Well, when Credit Suisse was in financial trouble, and the Swiss government had UBS takeover the company, those bonds became worthless, absolutely worthless, $17 billion up in smoke, you’re now seeing investors bringing claims Morgan Stanley, and other major firms like UBS and Credit Suisse sold these bonds to investors. [read post]
8 May 2023, 6:46 am by Brian D. Keppler, Ph.D.
In a recent decision, the Federal Circuit affirmed a non-infringement ruling in a case involving Canopy Growth Corporation and GW Pharmaceuticals, two major players in the cannabis industry. [read post]
5 May 2023, 11:00 pm
“In the event of a major grid shutdown, all sub-stations across the country will be tasked with pulling equipment to repair it. [read post]
From 2013 to 2019, Mallinson estimates annual licensing revenues of five major Western SEP holders to be stable at USD 10-11 billion. [read post]
27 Apr 2023, 2:43 pm by Roya Ghafele (OxFirst)
The SEPs Regulation Proposal indicates the European Commission’s desire to establish four major requirements for SEPs holders and implementers. [read post]